Shiloh
Editor, Senior Moderator
Source: http://www.todayonline.com/Singapore/EDC120313-0000081/One-step-closer-to-a-vaccine-for-HFMD
One step closer to a vaccine for HFMD
Vaccine to combat virulent EV71 strain could be in market in 2015
by Neo Chai Chin
Updated 06:08 PM Mar 14, 2012
SINGAPORE - With Hand, Foot and Mouth Disease (HFMD) hitting epidemic levels here, a vaccine against the virulent EV71 strain of the disease took a step closer to the market yesterday.
The INV21 vaccine could be the world's first - provided its developer Inviragen pips pharmaceutical companies in other parts of the world in rolling out a vaccine against a disease that Asian countries are increasingly grappling with.
As part of its first phase trial - done in collaboration with the National University Health System and Duke-NUS Graduate Medical School - the INV21 vaccine induced immune responses among all trial participants.
The clinical trial results of the INV21 vaccine are "very promising", said principal investigator Dr Paul Tambyah of the National University Hospital. "We look forward to continued collaboration on HFMD research and carrying out large-scale trials in partnership with Inviragen, to bring successful vaccine candidates such as INV21 closer to clinical use, to help protect vulnerable children in this part of the world."
The vaccine could be available in the market in 2015, Inviragen's...
One step closer to a vaccine for HFMD
Vaccine to combat virulent EV71 strain could be in market in 2015
by Neo Chai Chin
Updated 06:08 PM Mar 14, 2012
SINGAPORE - With Hand, Foot and Mouth Disease (HFMD) hitting epidemic levels here, a vaccine against the virulent EV71 strain of the disease took a step closer to the market yesterday.
The INV21 vaccine could be the world's first - provided its developer Inviragen pips pharmaceutical companies in other parts of the world in rolling out a vaccine against a disease that Asian countries are increasingly grappling with.
As part of its first phase trial - done in collaboration with the National University Health System and Duke-NUS Graduate Medical School - the INV21 vaccine induced immune responses among all trial participants.
The clinical trial results of the INV21 vaccine are "very promising", said principal investigator Dr Paul Tambyah of the National University Hospital. "We look forward to continued collaboration on HFMD research and carrying out large-scale trials in partnership with Inviragen, to bring successful vaccine candidates such as INV21 closer to clinical use, to help protect vulnerable children in this part of the world."
The vaccine could be available in the market in 2015, Inviragen's...